Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial

@inproceedings{Shi2015CisplatinCW,
  title={Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial},
  author={Yuankai Shi and Yi Hu and Xingsheng Hu and Xue Li and L Lin and Xiaohong Han},
  booktitle={Thoracic cancer},
  year={2015}
}
BACKGROUND This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). The relationship between UGT1A1 genotypes and patient outcomes was also assessed. METHOD Patients with untreated ES-SCLC were randomly assigned to receive either IP or EP, and blood specimens were collected to test the genotypes of UGT1A1*28 and UGT1A1… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 27 references

: Final patient - level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124

  • P Therasse, SG Arbuck, EA Eisenhauer
  • 2010

Similar Papers

Loading similar papers…